

APA519Ra01 100µg

**Active Apolipoprotein A1 (APOA1)** 

Organism Species: Rattus norvegicus (Rat)

Instruction manual

FOR RESEARCH USE ONLY
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

13th Edition (Revised in Aug, 2023)

#### [PROPERTIES]

Source: Prokaryotic expression.

Host: E. coli

Residues: Asp25~Ala259 Tags: N-terminal His-tag

**Purity: >90%** 

**Endotoxin Level:** <1.0EU per 1μg (determined by the LAL method). **Buffer Formulation:** PBS, pH7.4, containing 0.01% SKL, 5%Trehalose .

Original Concentration: 200µg/mL

**Applications:** Activity Assays.

(May be suitable for use in other assays to be determined by the end user.)

Predicted isoelectric point: 5.5

Predicted Molecular Mass: 31.1kDa

Accurate Molecular Mass: 27kDa as determined by SDS-PAGE reducing conditions.

### [USAGE]

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

#### [ STORAGE AND STABILITY ]

**Storage:** Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.

**Stability Test:** The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

### [SEQUENCE]

DEPQSQWDRVKDFATVYVDAVKDSGRDYVSQFESSTLGKQLNI NLLDNWDTLGSTVGRLQEQLGPVTQEFWANLEKETDWLRNEM NKDLENVKQKMQPHLDEFQEKWNEEVEAYRQKLEPLGTELHK NAKEMQRHLKVVAEEFRDRMRVNADALRAKFGLYSDQMRENL AQRLTEIKNHPTLIEYHTKASDHLKTLGEKAKPALDDLGQGLMP VLEAWKAKIMSMIDEAKKKLNA

#### [ACTIVITY]

Apolipoprotein A1 (APOA1) is the major protein component of HDL particles in plasma. It is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. ApoA1 was also isolated as a prostacyclin (PGI2) stabilizing factor, and thus may have an anticlotting effect. ApoA1 is often used as a biomarker for prediction of cardiovascular diseases. Besides, Plasminogen Activator, Urokinase (uPA) has been identified as an interactor of APOA1, thus a functional binding ELISA assay was conducted to detect the interaction of recombinant rat APOA1 and recombinant human uPA. Briefly, APOA1 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100 ul were then transferred to uPA-coated microtiter wells and incubated for 2h at 37 °C. Wells were washed with PBST and incubated for 1h with anti-APOA1 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37  $^{\circ}$ C. Finally, add 50  $\mu$ L stop solution to the wells and read at 450/630 nm immediately. The binding activity of recombinant rat APOA1 and recombinant human uPA was shown in Figure 1. The binding activity of recombinant rat APOA1 and recombinant human uPA was shown in Figure 1, and this effect was in a dose dependent manner.




Figure 1. The binding activity of recombinant rat APOA1 and recombinant human uPA

# [IDENTIFICATION]




Figure 2. SDS-PAGE

Sample: Active recombinant APOA1, Rat

# [ IMPORTANT NOTE ]

The kit is designed for research use only, we will not be responsible for any issue if the kit was used in clinical diagnostic or any other procedures.